Navigation Links
ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application
Date:3/1/2010

and uncertainties include, but are not limited to: FDA's requirements for the ANX-530 NDA to be accepted for review do not justify continued development of ANX-530; ADVENTRX's dependence on the success of ANX-530, and increased uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept a resubmitted ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; the potential for FDA to impose other requirements to be completed before or after approval of the ANX-530 NDA; ADVENTRX's reliance on third parties to assist with its bioequivalence trials, regulatory submissions, manufacturing and other important aspects of the ANX-530 development program, and the risk that FDA approval may be delayed if their performance is found to have been substandard; the possibility that patent claims covering ANX-530 will not issue or, if they do, that such claims, which likely will be limited to a specific intravenous emulsion formulation of vinorelbine, will not be sufficient to preclude development of other formulations of vinorelbine by competitors; the risk of investigator bias in reporting adverse events as a result of the open-label nature of the ANX-530 bioequivalence study, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; the risk that
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Announces Management Promotions
2. ADVENTRX Appoints Icahn Representative to Board of Directors
3. ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
4. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
5. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
6. ADVENTRX Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26
7. ADVENTRX Pharmaceuticals Announces Closing of Financing
8. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
9. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015  Fewer blockbusters drugs are expected to ... opportunities for generic companies in Asia ... looking beyond the patent cliff to focus on market ... established generic manufacturers are restructuring their business models and ... although the impact of these efforts will take a ...
(Date:4/20/2015)... , April 21, 2015  Following is the ... LIFESAVING MEDICINE ... most important medicines — insulin —became available for general ... millions of people suffering from diabetes. Insulin is a ... the processing of carbohydrates in the human body. It ...
(Date:4/20/2015)... This report analyzes the worldwide markets for Breast ... Breast Pumps, and Powered Breast Pumps. The report provides separate ... Japan , Europe , ... estimates and forecasts are provided for the period 2014 through ... markets. Market data and analytics are derived from primary and ...
Breaking Medicine Technology:Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 2Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 4Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 5U.S. Census Bureau Daily Feature for April 21 2World Breast Pumps Industry 2World Breast Pumps Industry 3World Breast Pumps Industry 4World Breast Pumps Industry 5World Breast Pumps Industry 6World Breast Pumps Industry 7World Breast Pumps Industry 8World Breast Pumps Industry 9World Breast Pumps Industry 10World Breast Pumps Industry 11World Breast Pumps Industry 12World Breast Pumps Industry 13World Breast Pumps Industry 14
... 2011 OncoMed Pharmaceuticals, Inc., a company developing novel ... publication of preclinical data demonstrating that its lead candidate, ... frequency when administered alone or in combination with chemotherapy ... mutations.  This study was published in the March 1, ...
... N.C., March 1, 2011 Max Neeman International has ... rare disease trials in response to sponsor demand. The ... to optimize complex study design.  Often strict inclusion/exclusion criteria ... greatest challenge for Biotech and Pharma that the company,s ...
Cached Medicine Technology:OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 2OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 3OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 4OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 5Max Neeman Develops Innovative Approach for Rare Disease Studies 2
(Date:4/21/2015)... Pharmacy point of sale software ... Independent Pharmacy Cooperative trade show, to be held April ... , Retail Management Solutions recently became an approved vendor ... Gross, VP of Sales and Marketing. Gross says that ... trade shows in the country -- and this new ...
(Date:4/21/2015)... Washington, Connecticut (PRWEB) April 21, 2015 ... were bathed in blue lights to draw attention to ... extra illumination during this time is the unique educational ... the autism spectrum is wide and diverse and each ... characteristic that remains constant. That is, the educational and ...
(Date:4/21/2015)... San Antonio, TX (PRWEB) April 21, 2015 ... reconstruction, PRMA is actively involved in various components ... basic science fields. , "Breast reconstruction ... outcomes following mastectomy. Despite recent advances, many ... order to provide patients with optimal results," says ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Lifeguard Master ... Straps offerings. All products are listed on the Lifeguard Master ... favorite of EMS workers who want a quality and flexible ... spokesperson, “Our Spider Straps and color Spider Straps are some ... to use and made of sturdy, heavy nylon” , The ...
(Date:4/21/2015)... 21, 2015 On May 12, ... opening of its Center for Graduate Studies, located ... Hospital. The campus recently completed a stunning renovation, ... thing that has administrators and students abuzz. ... the Master of Science in Nursing, Post-Master’s Family ...
Breaking Medicine News(10 mins):Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 2Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 3Health News:In Light of Autism Awareness Month,The Glenholme School Illuminates the Benefits of Therapeutic Boarding School for Students on the Spectrum 2Health News:In Light of Autism Awareness Month,The Glenholme School Illuminates the Benefits of Therapeutic Boarding School for Students on the Spectrum 3Health News:In Light of Autism Awareness Month,The Glenholme School Illuminates the Benefits of Therapeutic Boarding School for Students on the Spectrum 4Health News:Research Performed at PRMA Expands Breast Reconstruction Knowledge 2Health News:Research Performed at PRMA Expands Breast Reconstruction Knowledge 3Health News:Research Performed at PRMA Expands Breast Reconstruction Knowledge 4Health News:Research Performed at PRMA Expands Breast Reconstruction Knowledge 5Health News:New Spider Straps for Spine Boards are Introduced for Easy, Fast, and Convenient Use 2Health News:New Spider Straps for Spine Boards are Introduced for Easy, Fast, and Convenient Use 3Health News:New Spider Straps for Spine Boards are Introduced for Easy, Fast, and Convenient Use 4Health News:West Coast University Opens a Center for Graduate Studies 2Health News:West Coast University Opens a Center for Graduate Studies 3
... youth, former president Jimmy Carter recently mused Ive been a ... I interrelate with a wide range of studentsI dont detect ... to the exclusion of benevolent causes than others have been ... to support this notion. An article appearing in the ...
... World Health Organization (WHO) standard on fine particulate matter pollution ... concludes research in the Journal of Epidemiology and Community Health. ... fine particulate matter pollution (PM2.5) at 20 g/m 3 by ... US Environmental Protection Agency is 15 g/m 3, while ...
... 5,000 people around the world die from tuberculosis every day, ... it in 40 years. Researchers at the National High Magnetic ... through research made possible by a $2-million grant from the ... possible for Timothy A. Cross, the Earl Frieden Professor of ...
... Delhi and Singapore (January 17, 2008) SAGE, ... to continue its successful growth in public health ... the International Union for Health Promotion and Education ... Education. , Published quarterly, Promotion and Education is ...
... . , In the 1960s, Ancer Keys, ... of the Mediterranean diet for the first time. Since ... have been conducted. According to several studies performed in ... incidence of diseases is lower in these countries than ...
... a tumor of the nervous system in children, poses ... Center (Deutsches Krebsforschungszentrum, DKFZ) have been searching for substances ... drugs. Now they have found a candidate: HC-toxin, ... substance from the maize pathogen reprograms neuroblastoma cells in ...
Cached Medicine News:Health News:Europe should adopt WHO recommendations for particulate matter cuts 2Health News:Researcher, magnet lab receive $2 million grant to target tuberculosis 2Health News:Consuming extra virgin olive oil helps to combat degenerative diseases such as cancer 2Health News:Plant pathogen yields substance to fight neuroblastoma 2
... design allows "Four gels in one tank" electrophoresis. ... run 200 samples or more in one compact ... gels. To ensure even migration, the electrode height ... being run. Ideal for high throughput procedures, an ...
... tanks come with turn and cast gel ... pouring as simple as possible. , ... your application. Avaialble in a variety of ... gel size right up to the 20 ...
... UniPhor units can be used for: ... and non denaturing SDS-PAGE gels IEF ... Z64,075 1) Preparative Protein and Peptide ... gels IEF in Agarose Ampholyte Gels ...
... Horizontal Gel System provides a compact format ... DNA fragments, PCR products and synthetic oligonucleotides, ... The Mini Horizontal Unit has gel bed ... The gel bed is UV transparent. Adjustable ...
Medicine Products: